TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01743404

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Inflaminat

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill manufactured to mimic Inflaminat 500 mg tablet
Study: NCT04311827

Intervention type: OTHER
Intervention: Serratus Anterior Plane Block
Description: Injection of bupivacaine 75mg above the serratus anterior facial plane in the anterior axillary line
Study: NCT04485572

Intervention type: DIAGNOSTIC_TEST
Intervention: Straight Leg Raise test (SLR) and Bragard test (B)
Description: The following neurodynamic and/or orthopedic tension tests were done: the Straight Leg Raise test (SLR), the Bragard test (B) and another test which was the combined test of both (SLR+B)

Intervention type: DIAGNOSTIC_TEST
Intervention: Fajersztajn test (F) and Sicard test (S)
Description: The following neurodynamic and/or orthopedic tension tests were done: the Fajersztajn test (F), the Sicard test (S) and another test which was the combination of both (F+S)

Intervention type: DIAGNOSTIC_TEST
Intervention: Passive Neck Flexion test (PNF)and Kernig test (K)
Description: The following neurodynamic and/or orthopedic tension tests were done: the Passive Neck Flexion test (PNF), the Kernig test (K) and another test which was the combination of both (PNF+K)

Intervention type: DIAGNOSTIC_TEST
Intervention: Slump test (ST) and Dejerine triad (DT)
Description: The following neurodynamic and/or orthopedic tension tests were done: the Slump test (ST), the Dejerine triad (DT) and another test which was the combination of both (ST+DT)

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI scan
Description: All participants will undergo a MRI scan to compare results between the index tests and the Gold Standard

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI scan
Description: All participants will undergo a MRI scan to compare results between the index tests and the Gold Standard

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI scan
Description: All participants will undergo a MRI scan to compare results between the index tests and the Gold Standard

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI scan
Description: All participants will undergo a MRI scan to compare results between the index tests and the Gold Standard
Study: NCT03568955

Intervention type: DIAGNOSTIC_TEST
Intervention: International Prolonged Grief Disorder Scale (IPGDS)
Description: Assessment measure for Prolonged Grief disorder based on the ICD-11 (International Classification of Disorders) criteria for PGD (Prolonged Grief Disorder). 15 items

Intervention type: DIAGNOSTIC_TEST
Intervention: International Prolonged Grief Disorder Scale (IPGDS)
Description: Assessment measure for Prolonged Grief disorder based on the ICD-11 (International Classification of Disorders) criteria for PGD (Prolonged Grief Disorder). 15 items

Intervention type: DIAGNOSTIC_TEST
Intervention: International Prolonged Grief Disorder Scale (IPGDS)
Description: Assessment measure for Prolonged Grief disorder based on the ICD-11 (International Classification of Disorders) criteria for PGD (Prolonged Grief Disorder). 15 items
Study: NCT00677755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mifepristone combined misoprostol
Description: women received a single dose of mifepristone (Mifepristone tablets; Xianju Pharmacy, Zhejiang, China) 200mg orally on day 1, and then returned to the clinic on day 3 and were given misoprostol (Cytotec tables; Searle,A Division of Monsanto.P.L.C, England )0.8mg orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: misoprostol alone protocol
Description: patients were only administered 0.8 mg of misoprostol orally on day 3.
Study: NCT01883648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coconut Oil Beverage
Description: There are 2 treatment arms: Fuel for Thought™ and placebo, with a treatment allocation of 1:1. After 3 months of treatment in one group, subjects will have a 3-5 day wash-out period before receiving the alternate (opposite) treatment for 3 months.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Beverage
Description: There are 2 treatment arms: Fuel for Thought™ and placebo, with a treatment allocation of 1:1. After 3 months of treatment in one group, subjects will have a 3-5 day wash-out period before receiving the alternate (opposite) treatment for 3 months.
Study: NCT03283397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EK-12
Description: 10 mg metenkefalin acetate + 2 mg tridecactide acetate in 2 mL 0.9 % NaCl solution.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: INF beta-1a
Description: Active substance is INF beta-1a, 44 mcg in 0.5 mL solution
Study: NCT02964832

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Grasp method

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Armband-in-hand method

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Armband-on-arm method
Study: NCT01651390

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Description: Up to 140 patients meeting the inclusion criteria and none of the exclusion criteria are randomly selected and stratified according to diabetic status at screening are treated with the Pantera Lux drug coated balloon.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention
Description: Up to 70 patients meeting the inclusion criteria and none of the exclusion criteria are randomly selected and stratified according to diabetic status at screening are treated with the Orsiro drug eluting stent.
Study: NCT02177019

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized health plan
Study: NCT03209427

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine 200 μg
Description: Intrathecal injection of morphine 200 μg
Study: NCT04313322

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WJ-MSCs
Description: WJ-MSCs will be derived from cord tissue of newborns, screened for HIV1/2, HBV, HCV, CMV, Mycoplasma, and cultured to enrich for MSCs.~WJ-MSCs will be counted and suspended in 25 ml of Saline solution containing 0.5% human serum Albumin, and will be given to patient intravenously.
Study: NCT03386734

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SLN biopsy only
Description: In experimental arm, SLN dissection only. A full lymphadenectomy will not be performed. The radical hysterectomy or trachelectomy will be done.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SLN biopsy + PLN dissection
Description: In active comparator arm, SLN dissection + full lymphadenectomy will be performed.
Study: NCT02595697

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: J-EMT for Toddlers with Autism
Description: Children assigned to the J-EMT group will receive a total of 48, 1-hour direct intervention sessions over six months that will include teaching their parents to implement J-EMT procedures across daily activities.
Study: NCT04366375

Intervention type: DIAGNOSTIC_TEST
Intervention: PTX-3
Description: Pentraxin-3 ng/mL PTX-3 levels were measured using human PTX3 ELISA Kit 96 Tests/Box (Cat. No: CK-E90303) (Hangzhou Eastbiopharm Co.,Ltd., PRC) read by a ELISA device matching with the kit. For the purpose of measurement, microplate washer RT 2600 device and Rayto microplate reader RT 2100C device were used.

Intervention type: DIAGNOSTIC_TEST
Intervention: PTX-3
Description: Pentraxin-3 ng/mL PTX-3 levels were measured using human PTX3 ELISA Kit 96 Tests/Box (Cat. No: CK-E90303) (Hangzhou Eastbiopharm Co.,Ltd., PRC) read by a ELISA device matching with the kit. For the purpose of measurement, microplate washer RT 2600 device and Rayto microplate reader RT 2100C device were used.
Study: NCT03561701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oteseconazole (VT-1161)
Description: Oteseconazole (VT-1161) 150mg capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo capsule
Study: NCT01347255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO90100 cutaneous spray, ointment
Description: once daily application, 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LEO 90100 cutaneous spray, ointment, vehicle with betamethasone dipropionate
Description: once daily application, 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LEO 90100 cutaneous spray, ointment, vehicle
Description: once daily application, 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daivobet® ointment
Description: once daily application, 4 weeks
Study: NCT03654001

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Albumin
Description: Human Albumin In parallel with fluid administration for volume resuscitation, patients will receive 400 ml of 20% albumin solution both at randomization (D0) and at day 1 (D1). Subsequently, from day 2 (D2) until day 90 (D90) or ICU discharge (whichever comes first), 20% albumin will be administered on a daily basis, to maintain serum albumin concentration equal to or greater than 30 g/L, based upon serum albumin determination.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Albumin
Description: Human Albumin In parallel with fluid administration for volume resuscitation, patients will receive 400 ml of 20% albumin solution both at randomization (D0) and at day 1 (D1). Subsequently, from day 2 (D2) until day 90 (D90) or ICU discharge (whichever comes first), 20% albumin will be administered on a daily basis, to maintain serum albumin concentration equal to or greater than 30 g/L, based upon serum albumin determination.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balanced
Description: Balanced crystalloid solutions are traditionally crystalloid solutions containing a relatively low concentration of chloride as compared to 0.9% NaCl containing solutions (Normal Saline).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balanced
Description: Balanced crystalloid solutions are traditionally crystalloid solutions containing a relatively low concentration of chloride as compared to 0.9% NaCl containing solutions (Normal Saline).
Study: NCT01765153

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Endurance
Description: Participants are trained daily to walk on a treadmill for as fast and as long as possible. A harness supporting part of their body weight can be used if needed. Assistance from a trainer is used if needed. A physical therapist supervises the training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Endurance
Description: Participants are trained daily to walk on a treadmill for as fast and as long as possible. A harness supporting part of their body weight can be used if needed. Assistance from a trainer is used if needed. A physical therapist supervises the training.
Study: NCT02496169

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eucaLimus
Description: Percutaneous Coronary Intervention (PCI)
Study: NCT00391001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taurine
Description: double-blind, placebo-controlled, adjunctive medication

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Taurine
Description: double-blind, placebo-controlled, adjunctive medication
Study: NCT01904656

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Get Behind your health
Description: Participants are exposed to the Get Behind Your Health! media campaign intervention comprising 3 phases: the media campaign, the medical chart reminder, and a combination of media campaign and chart reminder. Participants also undergo telephone interviews during years 2-4.
Study: NCT01765153

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Precision
Description: Participants train daily to walk over ground on 15 m straight hallway with obstacles they must step over, and targets they must step onto.
Study: NCT03032627

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Collection of discarded heart tissue
Description: Discarded heart tissue will be collected from patients undergoing the aforementioned cardiac surgeries.
Study: NCT03340662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-122
Description: CC-122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-122
Description: CC-122
Study: NCT04320043

Intervention type: PROCEDURE
Intervention: Anterior cervical decompression
Description: Any of the following anterior surgical techniques used to decompress the cervical nerve roots or spinal cord; corpectomy, Anterior Cervical Discectomy (ACD), Anterior Cervical Decompression and Fusion (ACDF) or ACDF with Plating
Study: NCT01904656

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Peaches
Description: Participants are exposed to a Healthy Eating! media campaign intervention comprising 3 phases: the media campaign, the medical chart reminder, and a combination of media campaign and chart reminder. Participants also undergo telephone interviews during years 2-4.
Study: NCT04425785

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Exercise Program
Description: A structured exercise program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy
Description: A structured cognitive behavioural therapy program
Study: NCT01511809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir monotherapy
Description: Monotherapy Simplification Strategy with Atazanavir/ritonavir 300/100 mg once daily for 96 weeks.
Study: NCT00889200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eszopiclone
Description: 6 weeks standard oral therapy
Study: NCT05485142

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: prolotherapy
Description: 5% glucose 10ml local injection peripheral to posterior tibial nerve near ankle under ultrasound guidance once a week for 4 weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: prolotherapy
Description: 5% glucose 10ml local injection peripheral to posterior tibial nerve near ankle under ultrasound guidance once a week for 4 weeks.
Study: NCT00275756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timolol (drug)
Description: Timolol (0.5%, non-selective beta-blocker, Timoptic®, Merck Sharp \& Dohme, Haarlem, Netherlands), dose 1 drop in one eye twice daily for two weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dorzolamide (drug)
Description: Dorzolamide (2%, carbonic anhydrase inhibitor, Trusopt®, Laboratoires Merck Sharp \& Dohme - Chibret, France), dose: 1 drop in one eye twice daily for two weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brimonidine (drug)
Description: Brimonidine (0.2%. alpha-2 adrenergic agonist, Alphagan®, Allergan Pharmaceuticals, Westport, Ireland), dose: 1 drop in one eye twice daily for two weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Doppler flowmetry
Description: blood flow measurements at the temporal neuroretinal rim of the optic nerve head, in total 4x 9 minutes on 2 study days

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Doppler flowmetry
Description: blood flow measurements at the temporal neuroretinal rim of the optic nerve head, in total 4x 9 minutes on 2 study days

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Doppler flowmetry
Description: blood flow measurements at the temporal neuroretinal rim of the optic nerve head, in total 4x 9 minutes on 2 study days

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Goldmann applanation tonometer
Description: intraocular pressure measurements, in total 2x 5 measurements on two study days

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Goldmann applanation tonometer
Description: intraocular pressure measurements, in total 2x 5 measurements on two study days

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Goldmann applanation tonometer
Description: intraocular pressure measurements, in total 2x 5 measurements on two study days

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suction cup method
Description: The IOP will be raised by an 11 mm diameter, standardized suction cup placed on the temporal sclera with the anterior edge at least 1 mm from the limbus; 4x 8 minutes on 2 study days

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suction cup method
Description: The IOP will be raised by an 11 mm diameter, standardized suction cup placed on the temporal sclera with the anterior edge at least 1 mm from the limbus; 4x 8 minutes on 2 study days

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suction cup method
Description: The IOP will be raised by an 11 mm diameter, standardized suction cup placed on the temporal sclera with the anterior edge at least 1 mm from the limbus; 4x 8 minutes on 2 study days
Study: NCT01747252

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: RGC

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: RGC

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Resveratrol
Description: The equivalent of 150 mg resveratrol
Study: NCT00130923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone Long Acting
Description: Dose 25.00, 37.50 or 50.00 mg q two weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral risperidone
Description: 0.50-6.00 mg oral risperidone daily
Study: NCT00360828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride (HCI) Treatment
Description: Irinotecan injections. Irinotecan hydrochloride \[CPT-11; CAMPTOSAR\] is an antineoplastic agent of the topoisomerase I inhibitor class. The drug is supplied in amber vials and appears as a pale yellow transparent aqueous solution. Two vial sizes are available: 2 mL vials containing 40 mg of drug and 5 mL vials containing 100 mg of drug. A treatment cycle was 21 days. Patients were treated for a minimum of 3 cycles (doses) of CPT-11 or until their disease progressed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continued Irinotecan Hydrochloride (HCI) Treatment
Description: For patients responding to treatment, therapy could have continued beyond 18 cycles.
Study: NCT00991666

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: blood flow measurement
Description: Fundus pulsation amplitude measurement Pulsatile ocular blood flow measurement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: blood flow measurement
Description: Fundus pulsation amplitude measurement Pulsatile ocular blood flow measurement
Study: NCT01848587

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Study: NCT03070379

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Topical lidocaine pharyngeal anesthesia
Description: Topical pharyngeal anesthesia by lidocaine was administrated 4-5 min before propofol sedation in patients who underwent esophagogastroduodenoscopy.
Study: NCT03821298

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care Hand Therapy
Description: 8 sessions 2 times a week for 4 weeks
Study: NCT01883414

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultherapy™
Description: All subjects will receive an Ultherapy™ treatment at triple depth using the 4-4.5mm, 7- 3.0mm, 10-1.5mm transducers on one half of the scar and no treatment on the other half of the scar. Treatments will be provided to the defined scar area, treating with a density of lines that is equivalent to 30 lines per transducer per 2.5cm in scar length for a total of 90 lines in a 2.5cm X 2.5cm square area.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultherapy™
Description: All subjects will receive an Ultherapy™ treatment at triple depth using the 4-4.5mm, 7- 3.0mm, 10-1.5mm transducers on one half of the scar and no treatment on the other half of the scar. Treatments will be provided to the defined scar area, treating with a density of lines that is equivalent to 30 lines per transducer per 2.5cm in scar length for a total of 90 lines in a 2.5cm X 2.5cm square area.
Study: NCT00555750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eszopiclone
Description: 3mg tablet, by mouth nightly 30 min before bed, for two months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: inactive placebo tablet, by mouth nightly 30 minutes before bed, for two months
Study: NCT02652416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1026706
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1026706
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1026706
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1026706
Description: oral administration
Study: NCT03160534

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: preoperative exercise
Description: Each intervention session contains a stretching part and aerobic training
Study: NCT02984189

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inspiratory muscle training
Description: The inspiratory muscle training (IMT) will be realized, to compare three intensities differents the training (Inspiratory critical pressure, 60% maximal inspiratory pressure and sham). The IMT will be performed for 11 weeks (33 sessions, 3 times/week, 1-hour duration). The session will consist of 5-min warm-up (50% of the training load) and 3 sets of 15 minutes (breathing against 100% of the training load) with 1-min interval between them, using a linear inspiratory load resistor (Device: PowerBreathe K5).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: The inspiratory muscle training (IMT) will be realized, to compare three intensities differents the training (Inspiratory critical pressure, 60% maximal inspiratory pressure and sham). The IMT will be performed for 11 weeks (33 sessions, 3 times/week, 1-hour duration). The session will consist of 5-min warm-up (50% of the training load) and 3 sets of 15 minutes (breathing against 100% of the training load) with 1-min interval between them, using a linear inspiratory load resistor (Device: PowerBreathe K5).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Inspiratory muscle training
Description: The inspiratory muscle training (IMT) will be realized, to compare three intensities differents the training (Inspiratory critical pressure, 60% maximal inspiratory pressure and sham). The IMT will be performed for 11 weeks (33 sessions, 3 times/week, 1-hour duration). The session will consist of 5-min warm-up (50% of the training load) and 3 sets of 15 minutes (breathing against 100% of the training load) with 1-min interval between them, using a linear inspiratory load resistor (Device: PowerBreathe K5).
Study: NCT00569296

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EGFRBi-armed autologous activated T cells
Description: Dose escalation, dosage depends on when entered in study. 8 infusions (twice a week over 4 weeks. Each infusion will be over at least 1 hour.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: 300,00IU/m2/day beginning 3 days before the first Activated T-cell infusion and ending 1 week after the last infusion